Gastric Cancer - Germany Drug Forecasts and Treatment Analysis to 2020

Report Overview

Table of Contents

2315.43

Select License Type

£2,315.43	Electronic License Electronic License An electronic version (mostly PDF, but can be Excel or PPT), which is either available for immediate download or will be sent via email by the Publisher of the report. The licencing for an electronic version is for use by the purchaser ONLY.
£4,630.85	Site License Site License An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is intended for use by more than one individual, across for example, a site, an office, or a division or country.
£6,946.28	Corporate License Corporate License An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is/are intended for use by an organisation in its entirety. For example, if reports are put on an Intranet or if they are distributed or used by more than one office, division, or country operation, then a Corporate Licence is required.

£2,315.43	Add to Wishlist
Change Currency	GBP EURO USD
	Order By Fax

Market	Healthcare and Medical
Report Type	Market Research
Country	Germany
Published	30 April 2011
Number of Pages	145
Report Delivery	Email
Delivery Lead Time	1-3 hours, 24 hour max
Publisher	GlobalData
File Format	PDF

Gastric Cancer - Germany Drug Forecasts and Treatment Analysis to 2020 - Global Data, the industry analysis specialist, has released its new report, "Gastric Cancer - Germany Drug Forecasts and Treatment Analysis to 2020". The report is an essential source of information and analysis on the Germany gastric cancer therapeutics market. The report provides comprehensive information on gastric cancer, highlighting the treatment guidelines. It identifies and analyses the key trends shaping and driving the Germany gastric cancer therapeutics market. It analyses the treatment usage patterns in the Germany gastric cancer therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the Germany gastric cancer sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Global Data's team of industry experts.

Scope

- An overview of gastric cancer which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized Germany gastric cancer therapeutics market revenue, annual cost of therapy and treatment usage patterns data (for hormone therapy and hormone resistant or refractory therapy) from 2001 to 2009, forecast for 11 years to 2020.
- Insightful review of the key industry drivers, restraints and challenges and predicted impact of key events.
- Competitor assessment including drug launch analysis and drug sales forecasts.
- Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals, product positioning and drug sales forecast.
- Analysis of unmet need in the market and target product profile including opportunity for target product.
- Technology trends analytic framework to assess strength of pipeline.
- Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include vascular endothelial growth factor (VGEF) inhibitors, tubulin inhibitors, topoisomerase inhibitors, mammalian target of rapamycin (mTOR) inhibitors and DNA synthesis inhibitors.
- Clinical trials mapping of trials for gastric cancer in Germany.
- An overview of the most promising drugs' including clinical study details, efficacy, safety, collaboration agreements, marketing rights, and launch analysis and drug sales forecasts to 2020.
- Analysis of the current and future market competition in the Germany Gastric Cancer therapeutics market. Company profiles including business description, financial overview and SWOT analysis. Key market players covered include Sanofi-aventis, Novartis AG, GlaxoSmithKline, Hoffmann-La Roche Ltd., Eli Lilly and Company, Otsuka and Merck KGaA.
- Analysis of licensing agreements during 2009-2010 in the gastric cancer therapeutics market. M&A analysis which includes M&A deals by size and geography.
- Strategic assessment of the market through market impact analysis, future market scenario and company analysis.
- Direct quotes from key opinion leaders (KOL) or physicians in the gastric cancer therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop business strategies and perform superior market quantification analysis by
- Understanding the trends shaping and driving the Germany gastric cancer therapeutics market.
- Understanding treatment preferences of physicians in disease state and across treatment flow.
- Accessing market sizing, forecasts and quantified growth opportunities in the Germany gastric cancer therapeutics market till 2020.
- Quantifying patient population in the Germany gastric cancer market to better design product pricing & launch plans.
- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by
- Performing benchmarking analysis and growth opportunities against currently marketed products
- Identifying market entry points based on safety, efficacy, and pricing parameters.
- Assessing competitiveness of products in market by understanding the strength and weakness of current competition.
- Develop and design your in-licensing and out-licensing strategies by
- taking a comprehensive look of at the disease pipeline and identifying most promising paradigm shifting products.
- Assessing strength of pipeline bases on first in class, me-too, generic and lifecycle management of products.
- Track drug sales in the Germany gastric cancer therapeutics market from 2001 to 2020
- Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.
- What's the next big thing in the Germany gastric cancer therapeutics market landscape? Identify, understand and capitalize

Speak to an Advisor

Call us on
+44 (0) 203 086 8600

Select License Type

£2,315.43	Electronic License Electronic License An electronic version (mostly PDF, but can be Excel or PPT), which is either available for immediate download or will be sent via email by the Publisher of the report. The licencing for an electronic version is for use by the purchaser ONLY.
£4,630.85	Site License Site License An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is intended for use by more than one individual, across for example, a site, an office, or a division or country.
£6,946.28	Corporate License Corporate License An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is/are intended for use by an organisation in its entirety. For example, if reports are put on an Intranet or if they are distributed or used by more than one office, division, or country operation, then a Corporate Licence is required.

£2,315.43	Add to Wishlist
Change Currency	GBP EURO USD

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Disease Overview
2.1.1 TNM (Tumor, Nodes, Metastasis) Staging System
2.2 Epidemiology
2.3 Etiology
2.4 Symptoms
2.4.1 Initial Symptoms
2.4.2 Symptoms Observed in Later Stages
2.5 Diagnosis
2.5.1 Fecal Occult Blood Test (FOBT)
2.5.2 X-ray of Upper Gastrointestinal Tract (GI Series)
2.5.3 Endoscopy (Gastroscopy)
2.5.4 Computed Tomography (CT)
2.5.5 Biopsy
2.6 Pathology
2.6.1 Grading
2.7 Prognosis
2.8 Treatment
2.8.1 Gastric Cancer Treatment Options
2.9 Treatment Guidelines
2.10 GlobalData Report Guidance

3 Market Characterization
3.1 Germany
3.1.1 Market Size
3.1.2 Drivers and Restraints
3.1.3 Impact on the Market
3.1.4 Forecasts
3.1.5 Drug Sales
3.1.6 Pricing and Reimbursements
3.2 Key Takeaway

4 Gastric Cancer Market: Competitive Assessment
4.1 Strategic Competitor Assessment
4.1.1 Overview
4.1.2 Benchmarking
4.1.3 Current Competitor Assessment
4.2 Launch Analysis and Sales Forecasts
4.3 Product Profiles of Major Marketed Drugs in the Gastric Cancer Market
4.3.1 Herceptin (trastuzumab)
4.3.2 Taxotere (docetaxel)
4.3.3 Xeloda
4.4 Key Takeaway

5 Gastric Cancer Market: Pipeline Assessment
5.1 Overview
5.2 Pipeline Analysis by Phase of Development
5.3 Pipeline by Mechanism of Action
5.4 Strategic Pipeline Assessment
5.4.1 Technology Trends Analytic Framework
5.5 Gastric Cancer – Promising Drugs Under Clinical Development
5.6 Partners in Development
5.6.1 Licensing Agreements
5.6.2 Research and Development Partnership Agreements
5.6.3 Technology and Diagnostic Agreements
5.7 Molecule Profile for Promising Drugs Under Clinical Development
5.7.1 Tykerb (Lapatinib)
5.7.2 Afinitor (Everolimus)
5.7.3 IMC-1121B (ramucirumab)
5.7.4 Cetuximab plus capecitabine and cisplatin
5.7.5 Apatinib (YN968DI)
5.8 Key Takeaway

6 Clinical Trials Mapping
6.1 Clinical Trials
6.1.1 Clinical Trials by Status
6.1.2 Clinical Trials by Country
6.1.3 Clinical Trials by Phase
6.1.4 Clinical Trials by Sponsor Type
6.1.5 Clinical Trials – Leading Sponsors
6.1.6 Clinical Trials – Leading Company Sponsors by Phase
6.2 Patient Recruitment

7 Opportunity and Unmet Need
7.1 Unmet Need
7.2 Opportunity for Target Products
7.3 Key Takeaway

8 Strategic Assessment
8.1 Key Events Impacting the Future Market
8.2 Market Impact Analysis
8.3 Future Market Scenario

9 Gastric Cancer Market: Future Players
9.1 Introduction
9.2 Novartis AG
9.2.1 Business Description
9.2.2 Financial Overview
9.2.3 Gastric Cancer Pipeline
9.2.4 SWOT Analysis
9.3 GlaxoSmithKline
9.3.1 Business Description
9.3.2 Financial Overview
9.3.3 Gastric Cancer Pipeline
9.3.4 SWOT Analysis
9.4 Hoffmann-La Roche Ltd.
9.4.1 Business Description
9.4.2 Financial Performance
9.4.3 Gastric Cancer Pipeline
9.4.4 SWOT Analysis
9.5 Eli Lilly and Company
9.5.1 Business Description
9.5.2 Financial Overview
9.5.3 Gastric Cancer Pipeline
9.5.4 SWOT Analysis
9.6 Otsuka Holdings Co., Ltd./Otsuka Pharmaceutical Co., Ltd.
9.6.1 Business Description
9.6.2 Gastric Cancer Products
9.7 Merck KGaA
9.7.1 Business Description
9.7.2 Financial Overview
9.7.3 Gastric Cancer Pipeline
9.7.4 SWOT Analysis

10 Gastric Cancer Market: Players in the Gastric Cancer Market
10.1 Sanofi-aventis
10.1.1 Business Description
10.1.2 Financial Overview
10.1.3 SWOT Analysis
10.1.4 Oncology Focus

11 M&A Analysis
11.1 Key Highlights
11.2 Key Deals' Analysis
11.2.1 CrystalGenomics Completes Merger with BexPharm
11.2.2 Astellas Pharma Acquires OSI Pharmaceuticals
11.2.3 Eli Lilly Acquires ImClone
11.2.4 Roche Acquires Additional 9.8% Stake in Chugai Pharmaceuticals

12 Expert Opinion
12.1 Germany

13 Appendix
13.1 Market Definitions
13.2 Abbreviations
13.3 Research Methodology
13.3.1 Coverage
13.3.2 Secondary Research
13.3.3 Forecasting
13.3.4 Primary Research
13.3.5 Expert Panel validation
13.3.6 Contact Us
13.3.7 Disclaimer
13.3.8 Sources

List of Tables

Table 1: Gastric Cancer Therapeutics Market, Global, Staging of Gastric Cancer, 2010
Table 2: Gastric Cancer Therapeutics Market, Global, Risk Factors, 2010
Table 3: Gastric Cancer, Global, Results of GI Series X-ray, 2010
Table 4: Gastric Cancer, Global, WHO Classification of Gastric Carcinomas, 2010
Table 5: Gastric Cancer, Global, Five Year Relative Survival by Stage, 2010
Table 6: Gastric Cancer, Global, Illustration of Subtotal and Total Gastrectomy, 2011
Table 7: Gastric Cancer Therapeutics Market, Germany, Sales Value ($m), 2002-2010
Table 8: Gastric Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 2002-2010
Table 9: Gastric Cancer Therapeutics Market, Germany, Patient Volume (Absolute), 2002-2010
Table 10: Gastric Cancer Therapeutics Market, Germany, Treatment Usage Patterns ('000s), 2002-2010
Table 11: Gastric Cancer Therapeutics Market, Germany, Sales Value ($m), 2010-2020
Table 12: Gastric Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 2010-2020
Table 13: Gastric Cancer Therapeutics Market, Germany, Patient Volume (Absolute), 2010-2020
Table 14: Gastric Cancer Therapeutics Market, Germany, Treatment Usage Patterns ('000s), 2010-2020
Table 15: Gastric Cancer Therapeutics Market, Germany, Gastric Cancer Drug Sales ($m), 2002-2010
Table 16: Gastric Cancer Therapeutics Market, Germany, Gastric Cancer Drug Sales ($m), 2011-2020
Table 17: Gastric Cancer, Global, Clinical Endpoints for Benchmarking, 2010
Table 18: Gastric Cancer, Global, Chemotherapy, Safety Profile of Approved Treatment, 2010
Table 19: Gastric Cancer, Global, Benchmarking of Major Marketed Products, 2010
Table 20: Gastric Cancer Therapeutics – Phase III Pipeline, 2010
Table 21: Gastric Cancer Therapeutics – Phase II Pipeline, 2010
Table 22: Gastric Cancer Therapeutics – Phase I Pipeline, 2010
Table 23: Gastric Cancer Therapeutics – Preclinical Pipeline, 2010
Table 24: Mechanism of Action for the 'Other' molecules in the Figure Above
Table 25: Gastric Cancer – Most Promising Drugs Under Clinical Development, 2010
Table 26: Gastric Cancer, Global, Licensing Agreements, 2007-2010
Table 27:Gastric Cancer, Global, Research and Development Partnership Agreements, 2009-2010
Table 28: Gastric Cancer, Global, Technology and Diagnostic Agreements, 2009-2010
Table 29: Gastric Cancer Therapeutics Market, Global, Clinical Trials by Status, January 2011
Table 30: Gastric Cancer Therapeutics Market, Global, Clinical Trials by Country, January 2011
Table 31: Gastric Cancer Therapeutics Market, Global, Clinical Trials by Phase, January 2011
Table 32: Gastric Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, January 2011
Table 33:Gastric Cancer Therapeutics Market, Global, Clinical Trials, Leading Sponsors, January 2011
Table 34:Gastric Cancer Therapeutics Market, Global, Clinical Trials, Leading Company Sponsors, January 2011
Table 35:Gastric Cancer Therapeutics Market, Global, Clinical Trials, Average Number of Patients Recruited, January 2011
Table 36: Novartis AG – Clinical Pipeline for Gastric Cancer, 2010
Table 37: GlaxoSmithKline – Clinical Pipeline for Gastric Cancer, 2011
Table 38: Roche – Clinical Pipeline for Gastric Cancer, 2011
Table 39: Eli Lilly and Company – Clinical Pipeline for Gastric Cancer, 2011
Table 40: Otsuka Holdings Co., Ltd. – Clinical Pipeline for Gastric Cancer, 2011
Table 41: Otsuka Holdings Co., Ltd. – Clinical Pipeline for Gastric Cancer, 2011
Table 42: Gastric Cancer, Global, M&A Deals, 2010

List of Figures

Figure 1: Gastric Cancer, Global, Illustration of Subtotal and Total Gastrectomy, 2011
Figure 2: Gastric Cancer Therapeutics Market, Global, Treatment Guidelines, 2010
Figure 3: Gastric Cancer Therapeutics Market, Germany, Sales Value ($m), 2002-2010
Figure 4: Gastric Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 2002-2010
Figure 5: Gastric Cancer Therapeutics Market, Germany, Patient Volume ('000s), 2002-2010
Figure 6: Gastric Cancer Therapeutics Market, Germany, Treatment Usage Patterns ('000s), 2002-2010
Figure 7: Gastric Cancer Therapeutics Market, Germany, Market Drivers and Restraints, 2009
Figure 8: Gastric Cancer Therapeutics Market, Germany, Historical Events Impact on the Market, 2010
Figure 9: Gastric Cancer Therapeutics Market, Germany, Sales Value ($m), 2010-2020
Figure 10: Gastric Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 2010-2020
Figure 11: Gastric Cancer Therapeutics Market, Germany, Patient Volume ('000s), 2010-2020
Figure 12: Gastric Cancer Therapeutics Market, Germany, Treatment Usage Patterns ('000s), 2010-2020
Figure 13: Gastric Cancer Therapeutics Market, Germany, Future Market Drivers and Restraints, 2010-2020
Figure 14: Gastric Cancer Therapeutics Market, Germany, Gastric Cancer Drug Sales ($m), 2002-2020
Figure 15: Gastric Cancer, Global, Strategic Competitor Assessment of Major Marketed Drugs, 2011
Figure 16: Gastric Cancer Therapeutics Market, Germany, Sales Forecast by Therapies, 2001-2020
Figure 17: Gastric Cancer, Germany, Herceptin, Sales ($m), 2010-2020
Figure 18: Gastric Cancer, Germany, Taxotere,, Sales ($m), 2006-2020
Figure 19: Gastric Cancer, Germany, Xeloda, Sales ($m), 2007-2020
Figure 20: Gastric Cancer, Global, Clinical Trials by Phase of Development, 2010
Figure 21: Gastric Cancer, Global, Pipeline by Mechanism of Action, 2010
Figure 22: Gastric Cancer, Global, Technology Trends Analytic Framework of Pipeline Drugs, 2011
Figure 23: Gastric Cancer, Global, Technology Trends Description of Pipeline Drugs, 2011
Figure 24: Gastric Cancer Therapeutics Market, Global, Clinical Trials by Status, January 2011
Figure 25: Gastric Cancer Therapeutics Market, Global, Clinical Trials by Country, January 2011
Figure 26: Gastric Cancer Therapeutics Market, Global, Clinical Trials by Phase, January 2011
Figure 27: Gastric Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, January 2011
Figure 28: Gastric Cancer Therapeutics Market, Global, Clinical Trials, Leading Sponsors, January 2011
Figure 29: Gastric Cancer Therapeutics Market, Global, Clinical Trials, Leading Company Sponsors, January 2011
Figure 30: Gastric Cancer Therapeutics Market, Global, Clinical Trials, Average Number of Patients Recruited, January 2011
Figure 31: Gastric Cancer, Germany, Median Overall Survival for Gastric Cancer Patients, 2011
Figure 32: Gastric Cancer, Germany, Opportunity and Unmet Need, 2010
Figure 33: Gastric Cancer, Global, Key Events Impacting the Future Market
Figure 34: Gastric Cancer, Germany, Implications for Future Market Competition, 2011
Figure 35: Gastric Cancer Therapeutic Market – Clinical Pipeline by Company, 2010
Figure 36: Gastric Cancer, Global, Novartis, SWOT Analysis 2010
Figure 37: Gastric Cancer, Global, GlaxoSmithKline, SWOT Analysis 2010
Figure 38: Gastric Cancer, Global, Roche, SWOT Analysis 2010
Figure 39: Gastric Cancer, Global, Eli Lilly and Company, SWOT Analysis 2010
Figure 40: Gastric Cancer, Global, Merck KGaA, SWOT Analysis 2010
Figure 41: Gastric Cancer, Sanofi-aventis, Major Pharmaceutical Drugs 2010
Figure 42: Gastric Cancer, Sanofi-aventis Pasteur, Diseases Under Each Vaccination Area 2010
Figure 43: Gastric Cancer, Global, Sanofi-aventis, SWOT Analysis, 2010
Figure 44: Gastric Cancer, Sanofi-aventis, Therapeutic Segment Share of Pipeline, 2010
Figure 45: Gastric Cancer, Germany, Key Data Inputs from KOL Interviews, July 2010
Figure 46: GlobalData Market Forecasting Model 143

Visitor Comments

All Comments

Change Currency

GBP

EURO

USD

Last Viewed

Gastric Cancer - Germany Drug Forecasts and Treatment Analysis to 2020

Healthcare and Medical Company Profiles

Find latest Healthcare and Medical Company Profiles with up to date financial, strategic, operational, SWOT analysis and product information for the leading healthcare and medical companies.

Competitor Tracking

Do you need to track your competitors and customers on a continuous basis? We have the expertise to provide you with a cost-effective, fully customised competitor tracking portal, which collates data on your competitors on a continuous basis. Contact us for a free consultation and demonstration.

Become an Affiliate

Do you manage an industry specific website or blog? Are you looking to monetise your web traffic further? Are you a B2B website?

Why not offer your visitors industry specific strategic market reports and company profiles? Our Affiliate Program enables you to provide quality content on your website and to earn money from passing on visitors to our website.

Custom Research

Cannot find what you need? We can tailor a report for you. Complete the Custom Research Form and we will provide a quote.

Healthcare and Medical	Type	Keywords Phrase All Words Any Word
Microsoft Windows users can hold the CTRL Key to select more than one sector or country at a time. Apple users can hold the CMD Key to do the same.	Country	Industry Sector
Publisher	Order By Relevance Date	Published In

Gastric Cancer - Germany Drug Forecasts and Treatment Analysis to 2020

Select License Type

Speak to an Advisor

Select License Type

Table of Contents

Visitor Comments

Change Currency

Last Viewed

Healthcare and Medical Company Profiles

Competitor Tracking

Become an Affiliate

Custom Research

News

Market Insights

Companies And Markets

Customer Support

Corporate Accounts

Contact Details

Contrast settings

Text size settings

All
Afghanistan
Africa
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antigua and Barbuda
Argentina
Armenia
Aruba
Asia
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia-Herzegovina
Botswana
Bouvet Island
Brazil
British Virgin Islands
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Caribbean
Cayman Islands
Central African Republic
Central America
Central Europe
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Conch Republic
Cook Islands
Costa Rica
Croatia
Cuba
Cyprus
Czech Republic
Democratic Republic of the Congo
Denmark
Djibouti
Dominica
Dominican Republic
Eastern Europe
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Europe
Falkland Islands
Faroe Islands
Fiji
Finland
France
French Guiana
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Global
Greece
Greenland
Grenada
Guadeloupe (French)
Guam (USA)
Guatemala
Guernsey
Guinea
Guinea Bissau
Guyana
Haiti
Heard Island and McDonald Islans
Holy See
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Ivory Coast
Ivory Coast (Cote D`Ivoire)
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Kurdistan
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique (French)
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Middle East
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
New Caledonia (French)
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North America
North Korea
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn Island
Poland
Polynesia (French)
Portugal
Puerto Rico
Qatar
Republic of the Congo
Reunion
Romania
Russia
Rwanda
Saint Barthelemy
Saint Helena
Saint Kitts and Nevis
Saint Lucia
Saint Martin
Saint Pierre and Miquelon
Saint Vincent and Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Scandinavia
Schengen countries
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South America
South Georgia and the South Sandwich Islands
South Korea
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen Islands
Swaziland
Sweden
Switzerland
Syria
Taiwan
Tajikistan
Tanzania
Thailand
Timor-Leste (East Timor)
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela
Vietnam
Virgin Islands
Wallis and Futuna Islands
Western Sahara
Yemen
Zambia
Zimbabwe

All
Aerospace
Agriculture, Farming & Raw Materials
Automotive and Parts
Business Services
Chemicals
Construction
Consumer Goods
Defence
Energy and Utilities
Environmental
Finance and Banking
Food and Drink
Healthcare and Medical
Industrial
Information Technology
Leisure
Logistics
Media
Paper and Packaging
Publishing and Printing
Real Estate
Retail
Security
Telecommunications
Textiles and Clothing
Transportation
Travel